Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | -0.660% | 4.505% | 6.081% | -8.627% | 5.999% | 53.692% | 131.748% |
| Incyte Corp. | 0.500% | -4.721% | -5.866% | 28.530% | -5.106% | 18.050% | 21.018% |
| IQVIA Holdings Inc. | 0.420% | -7.962% | -0.457% | -16.828% | -26.670% | -23.649% | -10.380% |
| Exact Sciences | -0.110% | 0.438% | 2.829% | 110.202% | 3.340% | 53.405% | -16.695% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.
Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.
Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.
Comments
News
Investment Firm Sheds 384,000 Shares of VERX Stock, According to Latest SEC Filing
On February 17, 2026, Tensile Capital Management LP reported selling 384,415 shares of Vertex (NASDAQ:VERX) in the fourth quarter, an estimated $8.32 million trade based on quarterly average
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree
Everyone should save money for retirement, since programs such as Social Security aren't meant to replace workers' entire income and face potential cuts. Building a big nest egg for your post-work
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously considered untreatable. That's why biotechs that specialize in gene